Trump Administration Announces 15 New Drugs for Medicare Price Negotiation

Treatments for diabetes, HIV, arthritis and other conditions included in latest round of negotiations.

Jan. 27, 2026 at 8:31pm

Got story updates? Submit your updates here. ›

The Trump administration has announced 15 new medications that will be subject to Medicare price negotiations, including drugs used to treat Type 2 diabetes, HIV, arthritis, and various other conditions. The negotiations are part of a 2022 law that allows the federal government to directly negotiate drug prices with manufacturers, with the goal of delivering significant savings to taxpayers when the negotiated prices go into effect in 2028.

Why it matters

The drugs selected for negotiation account for a significant portion of Medicare's total Part B and Part D spending, so the negotiated prices have the potential to generate substantial savings for the government and Medicare beneficiaries. This is the third round of the price negotiation program, which aims to address the long-standing issue of high prescription drug costs for seniors.

The details

The 15 drugs selected for negotiation this year include treatments for Type 2 diabetes, HIV, arthritis, psoriasis, ulcerative colitis, chronic lung disease, depression, and various cancers. Some of the specific drugs named are Trulicity, Biktarvy, and Botox. One drug, Tradjenta, which was previously negotiated, will undergo renegotiation. The negotiations will cover both Medicare Part B drugs (outpatient prescriptions) and Part D drugs (retail prescriptions).

  • The federal government had until February 1, 2026 to announce the list of 15 drugs.
  • The negotiated prices for these 15 drugs will go into effect in 2028.

The players

Centers for Medicare and Medicaid Services (CMS)

The federal agency that oversees the Medicare program and announced the list of 15 drugs selected for price negotiations.

Dr. Mehmet Oz

The CMS Administrator who stated that the negotiations will help target the most expensive drugs in Medicare and ensure the system works for patients, not special interests.

AARP

The leading advocacy organization for older Americans, which called the announcement a "significant step forward" in lowering drug prices for Medicare beneficiaries.

Pharmaceutical Research and Manufacturers of America (PhRMA)

The trade association for pharmaceutical companies, which criticized the Inflation Reduction Act that established the drug price negotiation program, arguing that government price setting is the wrong approach.

Got photos? Submit your photos here. ›

What they’re saying

“For too long, seniors and taxpayers have paid the price for skyrocketing prescription drug costs. Under President Trump's leadership, CMS is taking strong action to target the most expensive drugs in Medicare, negotiate fair prices, and make sure the system works for patients — not special interests.”

— Dr. Mehmet Oz, CMS Administrator (orovillemr.com)

“Older Americans across the political spectrum consistently say that lowering drug prices is a top priority, and we thank the Administration for protecting Medicare's ability to meet that need.”

— Dr. Myechia Minter-Jordan, AARP CEO (orovillemr.com)

“The IRA continues to show why government price setting is the wrong approach for Americans.”

— Elizabeth Carpenter, PhRMA Executive Vice President of Policy and Research (orovillemr.com)

What’s next

The negotiated prices for these 15 drugs will go into effect in 2028, providing potential savings for Medicare beneficiaries and taxpayers.

The takeaway

This latest round of Medicare drug price negotiations represents an ongoing effort to address the high cost of prescription drugs for seniors, with the potential to deliver significant savings through direct government negotiations with pharmaceutical companies.